Lightnews — Scholar-powered news

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 10d

9/29 I start at Mercy in St. Louis!
After reflection & emotional debate, we’ve moved to STL. Working at ZSFG/UCSF has been a profound privilege. The community, patients, & colleagues gave me more than I can ever express. Please know how grateful I am to have been part of this extraordinary team.

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · 20d

Thank you! Very honored!!

1

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Jun 9

Honored beyond words to receive the 2025 @ucsfmedicine.bsky.social at @zsfgcare.bsky.social Exceptional Physician Award. It is an incredible privilege to work alongside everyone across the SFHN. Thank you!

1 2

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · May 13

Short & sweet! Check out our review of #SGLT2i & #GLP1RA in #HeartFailure! Great work Jose Lopez & team! @ucsfcardiology.bsky.social @amitgoyalmd.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jimjanuzzi.bsky.social @sjgreene-md.bsky.social

www.uscjournal.com/articles/sho...

The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure

Heart failure (HF) affects 6 million people in the US, and type 2 diabetes (T2D) is a significant risk factor for HF. Since 2008, regulatory agencies have required cardiovascular safety trials

www.uscjournal.com

1 2 5

Reposted by Jonathan Davis, MD, MPHS

European Society of Cardiology @escardio.bsky.social · Apr 18

NEW! Patients versions of the #Hypertension guidelines

Need clear, reliable guidance for your patients with hypertension? The ESC has just released the patient-friendly version of its 2024 ESC Guidelines on management of elevated blood pressure and hypertension.

2 4 4

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Apr 16

#SGLT2i & #GLP1RA; not just for the heart... or kidneys... or diabetes! In ppl w DM2, GLP-1RAs & SGLT2is were associated w ⬇️ risk of Alzheimer disease & related dementias vs other glucose-lowering drugs. @robmentz.bsky.social @jama.com @noshreza.bsky.social @jimjanuzzi.bsky.social
ja.ma/3E3vWRn

GLP-1RAs and SGLT2is for Type 2 Diabetes and Alzheimer Disease

This population-based cohort study examines the association of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors with the risk of Alzheimer disease and related de...

ja.ma

3

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Jan 23

Thank you @sfchronicle.com for sharing Pamela's incredible journey from homelessness/addiction to ultimately 💓 transplant! Hopefully her story is can inspire pts & providers alike. @zsfgcare.bsky.social @ucsfhealth.bsky.social
www.sfchronicle.com/sf/article/h...

She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant

She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant.

www.sfchronicle.com

2 3

Reposted by Jonathan Davis, MD, MPHS

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 19

Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink.
@natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social
nature.com/articles/s44...

New and future heart failure drugs - Nature Cardiovascular Research

Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...

nature.com

2 2

Reposted by Jonathan Davis, MD, MPHS

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 19

Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social
www.jointcommission.org/resources/aw...

1 1

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 19

Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social
www.jointcommission.org/resources/aw...

1 1

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 19

Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink.
@natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social
nature.com/articles/s44...

New and future heart failure drugs - Nature Cardiovascular Research

Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...

nature.com

2 2

Reposted by Jonathan Davis, MD, MPHS

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 6

Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation.
@jaccjournals.bsky.social
www.sciencedirect.com/science/arti...

Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction

Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…

www.sciencedirect.com

6 7

Reposted by Jonathan Davis, MD, MPHS

Parham Eshtehardi MD @cardioobdoc.bsky.social · Dec 9

Management of Iron Deficiency in Heart Failure: Practical Considerations & Implementation of Evidence-Based Iron Supplementation

#CardioSky #JACCHF
@jaccjournals.bsky.social @robmentz.bsky.social @dranulala.bsky.social @hfsa.bsky.social @accintouch.bsky.social
www.jacc.org/doi/10.1016/...

1 6 10

Reposted by Jonathan Davis, MD, MPHS

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 6

Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD
#UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social

vimeo.com/1032042870/2...

1 2

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 6

Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD
#UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social

vimeo.com/1032042870/2...

1 2

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 6

Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation.
@jaccjournals.bsky.social
www.sciencedirect.com/science/arti...

Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction

Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…

www.sciencedirect.com

6 7

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 6

We are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure

1

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Dec 4

No plans this weekend? Not too late to sign up for the 41st Annual #UCSF #ZSFG Advances in Heart Disease CME! We have a fantastic lineup ready to go!
@accintouch.bsky.social @ahascience.bsky.social @hfsa.bsky.social @aspcardio.bsky.social

virtualce.ucsf.edu/advances-in-...

41st Annual Advances in Heart Disease

virtualce.ucsf.edu

2 1

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Nov 23

Novel ExCiTe approach aimed at improving trainee recruitment into AHFTC. Great work Edan Zitelny, Rachna Kataria & team @noshreza.bsky.social
@cardionerds.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jcardfail.bsky.social @shelleyzieroth.bsky.social
onlinejcf.com/article/S107...

7 15

Reposted by Jonathan Davis, MD, MPHS

Henry Han @hancardiomd.bsky.social · Nov 17

#Spironolactone given to patients who have undergone PCI following an #AMI has no impact on ☠️ from CV causes, or on a range of CV events including new or worsening HF ( #CLEAR SYNERGY )

www.tctmd.com/news/spirono...
@shelleywood.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

(UPDATED) Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV events.

www.tctmd.com

2 2

Reposted by Jonathan Davis, MD, MPHS

Parham Eshtehardi MD @cardioobdoc.bsky.social · Nov 17

#AHA24 #CardioSky

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Nov 16

1st post!

The 3 rules of #GDMTWorks for #HFrEF:
1. Start more
2.⬆️doses
3. Keep them going
#QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social

1 6

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Nov 16

@accintouch.bsky.social

2

Reposted by Jonathan Davis, MD, MPHS

Dr Martha Gulati @drmarthagulati.bsky.social · Nov 16

#LBCT #SUMMIT trial #AHA24
💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity
📎 @NEJM www.nejm.org/doi/full/10....

2 22 38

Reposted by Jonathan Davis, MD, MPHS

AHA Science @ahascience.bsky.social · Nov 16

BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg).

Watch this for one attendee’s take on the data.

9 9

Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Nov 16

1st post!

The 3 rules of #GDMTWorks for #HFrEF:
1. Start more
2.⬆️doses
3. Keep them going
#QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social

1 4 11